Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (7933)	12/3/1998 8:55:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

RobertS, The key words of Dr. Giroir were, "AGENT AVAILABLE". I read with care each one of your references. I was unable to find any reference to another agent that is available now to stop sepsis. I note that Integrilin was approved because apparently in 1,000 cases it can reduce death and or heart attacks by 1.5%. So I am not expecting that BPI is the be all, end all, cure for sepsis. It seems probable, that it will help somewhat. Do you think Neuprex or BPI will have absolutely no beneficial effect? Do you subscribe to Nature Biotechnology? Seems like experts in the field of sepsis, hold out more hope, even though they recognize BPI has drawbacks and that the ability to determine endotoxin levels may be critical to its' effective use. Have you ever worked with Dr. Opal? Do you consider him an expert in sepsis? I have no idea who he is and if you tell me he is wrong and is not the expert in sepsis that you are I will certainly disregard his opinion.